Q4 2025 Aarti Drugs Ltd Earnings Call Transcript
Key Points
- Aarti Drugs Ltd (BOM:524348) reported a 9% revenue growth in Q4 FY25, reaching INR679 crores, with improved EBITDA margins of 14%.
- The company experienced a 15.5% growth in API volumes, driven by strong global demand and stable input costs.
- PAT increased by 33% year-on-year to INR63 crores, with PAT margins at 9.2%.
- The company anticipates further improvement in gross margins due to expected uptake in selling price realization and enhanced capacity utilization.
- Aarti Drugs Ltd (BOM:524348) has resolved initial operational challenges at the Tarapur Greenfield project, aiming for significant production scale-up by FY26.
- FY25 was challenging due to muted global demand and elevated raw material costs, leading to a 5% year-on-year revenue decline.
- The API business saw a 4% revenue decline, attributed to transient corrections in global pricing and inventory cycles.
- The company faces geopolitical challenges that could impact profitability despite efforts in cost control and supply chain management.
- Export restrictions to Pakistan could impact sales, as exports to the country account for approximately 2.9% of total sales.
- The company revised its revenue target from INR4,000 crores to INR3,000 crores by FY27 due to price variations.
Ladies and gentlemen, good day and welcome to Aarti Drugs Limited, Q4 FY25 earnings conference call. (Operator instructions)
I now hand the conference over to Mr. Adhish Patil, COO and CFO of Aarti Drugs Limited.
Thank you and over to you, sir.
Thank you. Good morning, everyone. It is my pleasure to welcome you all to the earnings conference call of Aarti Drugs Limited. We thank you for taking the time to join us today to discuss our financial and operational performance for the fourth quarter and full year ended 31st March 2025.
Joining me on this call, Mr. Harshit Savla, Joint Managing Director; Mr. Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited, and our Investor Relations Advisor, SGA.
We hope that you have had the opportunity to review our financial results and investor presentation. Both of which have been uploaded on the stock exchanges and on our company's website.
In Q4 FY25, revenues grew by 9%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
